España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Arcus Biosciences
RCUS
NYSE
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$14.70
0.42
2.94%
At close: -
$14.28
-0.42
-2.86%
After Hours: Nov 22, 8:06 AM EDT
Get Report
Comment
Arcus Biosciences (RCUS) Forecast
News
Earnings
Arcus Biosciences (RCUS) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Arcus Biosciences (NYSE:RCUS) Stock
Arcus Biosciences Stock (NYSE: RCUS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, November 06, 2024
Arcus Biosciences Q3 2024 GAAP EPS $(1.00) Be...
Benzinga Newsdesk
Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts
Benzinga Insights
HC Wainwright & Co. Reiterates Neutral on Arc...
Benzinga Newsdesk
Tuesday, November 05, 2024
Arcus Biosciences Announces That Domvanalimab...
Benzinga Newsdesk
Friday, October 25, 2024
Barclays Maintains Overweight on Arcus Biosci...
Benzinga Newsdesk
Thursday, October 24, 2024
HC Wainwright & Co. Reiterates Neutral on Arc...
Benzinga Newsdesk
Arcus Biosciences shares are trading higher a...
Benzinga Newsdesk
Arcus Biosciences Presented The First Clinica...
Benzinga Newsdesk
Monday, October 21, 2024
Arcus Biosciences shares are trading lower. H...
Benzinga Newsdesk
Unveiling 5 Analyst Insights On Arcus Biosciences
Benzinga Insights
Where Arcus Biosciences Stands With Analysts
Benzinga Insights
HC Wainwright & Co. Initiates Coverage On Arc...
Benzinga Newsdesk
Tuesday, October 08, 2024
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Avi Kapoor
Wells Fargo Initiates Coverage On Arcus Biosc...
Benzinga Newsdesk
Monday, October 07, 2024
Cantor Fitzgerald Reiterates Overweight on Ar...
Benzinga Newsdesk
Thursday, October 03, 2024
Cantor Fitzgerald Reiterates Overweight on Ar...
Benzinga Newsdesk
Demystifying Arcus Biosciences: Insights From 4 Analyst Reviews
Benzinga Insights
Wedbush Reiterates Outperform on Arcus Biosci...
Benzinga Newsdesk
Wednesday, October 02, 2024
Arcus Biosciences Announces Clinical Trial Co...
Benzinga Newsdesk
Friday, August 09, 2024
Arcus Biosciences shares are trading higher a...
Benzinga Newsdesk
Breaking Down Arcus Biosciences: 4 Analysts Share Their Views
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Ar...
Benzinga Newsdesk
Wedbush Reiterates Outperform on Arcus Biosci...
Benzinga Newsdesk
Thursday, August 08, 2024
Arcus Biosciences Q2 2024 GAAP EPS $(1.02) Be...
Benzinga Newsdesk
Monday, July 08, 2024
Arcus Biosciences Says Taiho Exercised Its Op...
Benzinga Newsdesk
Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences
Benzinga Insights
Barclays Maintains Overweight on Arcus Biosci...
Benzinga Newsdesk
Friday, July 05, 2024
Cantor Fitzgerald Reiterates Overweight on Ar...
Benzinga Newsdesk
Monday, June 24, 2024
Truist Securities Maintains Buy on Arcus Bios...
Benzinga Newsdesk
Monday, June 10, 2024
Arcus Biosciences In Collaboration With Gilea...
Benzinga Newsdesk
Monday, June 03, 2024
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
Vandana Singh
Citigroup Maintains Buy on Arcus Biosciences,...
Benzinga Newsdesk
Sunday, June 02, 2024
Gilead And Arcus Announced Etrumadenant Plus Zimberelimab, FOLFOX, And Bevacizumab Reduce Death Risk By 63% And Disease Progression by 73% vs Regorafenib In Phase 1b/2 Trial For Third-Line Metastatic Colorectal Cancer
Charles Gross
Friday, May 24, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
Thursday, May 09, 2024
Wedbush Reiterates Outperform on Arcus Biosci...
Benzinga Newsdesk
Wednesday, May 08, 2024
Arcus Biosciences Q1 2024 GAAP EPS $(0.05) Be...
Benzinga Newsdesk
Wednesday, April 24, 2024
Arcus Biosciences To Present New Data From Ph...
Benzinga Newsdesk
Monday, March 25, 2024
Navigating 5 Analyst Ratings For Arcus Biosciences
Benzinga Insights
Truist Securities Reiterates Buy on Arcus Bio...
Benzinga Newsdesk
Thursday, February 22, 2024
Arcus Biosciences shares are trading higher a...
Benzinga Newsdesk
Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know
Benzinga Insights
Wedbush Reiterates Outperform on Arcus Biosci...
Benzinga Newsdesk
Wednesday, February 21, 2024
Recap: Arcus Biosciences Q4 Earnings
Benzinga Insights
Arcus Biosciences Q4 2023 GAAP EPS $(1.08) Mi...
Benzinga Newsdesk
Earnings Scheduled For February 21, 2024
Benzinga Insights
Tuesday, February 20, 2024
Preview: Arcus Biosciences's Earnings
Benzinga Insights
Thursday, February 01, 2024
$320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Avi Kapoor
Tuesday, January 30, 2024
Key Takeaways From Arcus Biosciences Analyst Ratings
Benzinga Insights
Wedbush Maintains Outperform on Arcus Bioscie...
Benzinga Newsdesk
Mizuho Maintains Buy on Arcus Biosciences, Lo...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
